Reviewing iRadimed Corporation (IRMD) & Tactile Systems Technology (TCMD)

iRadimed Corporation (NASDAQ: IRMD) and Tactile Systems Technology (NASDAQ:TCMD) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitabiliy, earnings, dividends and risk.

Valuation & Earnings

This table compares iRadimed Corporation and Tactile Systems Technology’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
iRadimed Corporation $24.35 million 4.28 $4.51 million $0.24 40.63
Tactile Systems Technology $97.23 million 5.45 $3.09 million $0.25 125.20

iRadimed Corporation has higher revenue, but lower earnings than Tactile Systems Technology. iRadimed Corporation is trading at a lower price-to-earnings ratio than Tactile Systems Technology, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares iRadimed Corporation and Tactile Systems Technology’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
iRadimed Corporation 11.61% 8.98% 7.69%
Tactile Systems Technology 4.97% 3.05% 2.54%

Institutional & Insider Ownership

15.9% of iRadimed Corporation shares are owned by institutional investors. Comparatively, 34.7% of Tactile Systems Technology shares are owned by institutional investors. 60.1% of iRadimed Corporation shares are owned by company insiders. Comparatively, 49.9% of Tactile Systems Technology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and price targets for iRadimed Corporation and Tactile Systems Technology, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
iRadimed Corporation 0 0 1 0 3.00
Tactile Systems Technology 0 0 4 0 3.00

iRadimed Corporation currently has a consensus price target of $12.00, indicating a potential upside of 23.08%. Tactile Systems Technology has a consensus price target of $33.00, indicating a potential upside of 5.43%. Given iRadimed Corporation’s higher probable upside, research analysts plainly believe iRadimed Corporation is more favorable than Tactile Systems Technology.

iRadimed Corporation Company Profile

IRADIMED CORPORATION (IRADIMED) develops, manufactures, markets and distributes Magnetic Resonance Imaging (MRI) compatible products, and provides non-magnetic intravenous (IV) infusion pump systems. The Company operates through development, manufacture and sale of MRI compatible products and IV infusion pump systems for use by hospitals and acute care facilities during MRI procedures segment. Its MRidium MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor, non-ferrous part and other features in order to deliver anesthesia and other IV fluids during various MRI procedures. MRI compatible IV infusion pump system includes the 3860+ MRI compatible IV infusion pump, single-use IV tubing sets, a non-magnetic pole and a lithium battery. In addition, it offers optional upgrade systems, including the 3865 Remote Display/Control, 3861 Side Car, Dose Error Reduction System (DERS) and SpO2 monitor.

Tactile Systems Technology Company Profile

Tactile Systems Technology, Inc. is a medical technology company that develops and provides medical devices for the treatment of chronic diseases at home. The Company is a manufacturer and distributor of the Flexitouch and Entre Systems, medical devices that help control symptoms of lymphedema, a chronic and progressive medical condition that is often an unintended consequence of cancer treatment, and the ACTitouch System, a medical device used to treat venous leg ulcers and chronic venous insufficiency. Its products deliver long-term treatment of chronic diseases. The Company provides its products for use in the home and sells them through vascular, wound and lymphedema clinics throughout the United States. The Company offers a platform to deliver at-home healthcare solutions throughout the United States. Its initial area of therapeutic focus is vascular disease, with a focus on advancing the care in treating lymphedema and chronic venous insufficiency.

What are top analysts saying about iRadimed Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for iRadimed Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit